MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
1.450
+0.050
+3.57%
After Hours: 1.450 0 0.00% 19:30 10/09 EDT
OPEN
1.410
PREV CLOSE
1.400
HIGH
1.490
LOW
1.370
VOLUME
91.48K
TURNOVER
--
52 WEEK HIGH
6.52
52 WEEK LOW
1.340
MARKET CAP
13.71M
P/E (TTM)
-0.3156
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 5d ago
Weekly Report: what happened at CLRB last week (0928-1002)?
Weekly Report · 10/05 10:13
Cellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia
NASDAQ · 09/29 11:53
Cellectar Biosciences to present data from Phase 2 CLOVER WaM trial
TipRanks · 09/29 11:40
Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenström Macroglobulinemia
Barchart · 09/29 06:30
Weekly Report: what happened at CLRB last week (0921-0925)?
Weekly Report · 09/28 10:09
Weekly Report: what happened at CLRB last week (0914-0918)?
Weekly Report · 09/21 10:09
Weekly Report: what happened at CLRB last week (0907-0911)?
Weekly Report · 09/14 10:14
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.